Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 35, Issue 11, Pages 39-47Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2014.09.002
Keywords
rapamycin; mTOR; autophagy; Beclin 1; aggregation; neurodegenerative disease
Categories
Funding
- FONDECYT [1140549, 11121524]
- Millennium Institute [P09-015-F]
- CONICYT [USA2013-0003, PAI 7912010006]
- ECOS-CONICYT [C13S02]
- Michael J. Fox Foundation for Parkinson's Research
- ALS Therapy Alliance
- Muscular Dystrophy Association
- Alzheimer's Disease Association
- Ring Initiative [ACT1109]
- FONDEF [D11I1007]
- Foundation COPEC-UC
Ask authors/readers for more resources
The most prevalent neurodegenerative disorders involve protein Autophagy is becoming an attractive target to treat neurodegenerative disorders through the selective degradation of abnormally folded proteins by the lysosomal pathway. However, accumulating evidence indicates that autophagy impairment at different regulatory steps may contribute to the neurodegenerative process. Thus, a complex scenario is emerging where autophagy may play a dual role in neurodegenerative diseases by causing the downstream effect of promoting the degradation of misfolded proteins and an upstream effect where its deregulation perturbs global proteostasis, contributing to disease progression. Challenges in the future development of therapeutic strategies to target the autophagy pathway are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available